ClinicalTrials.gg
CompletedNCT00764868Updated Jun 14, 2021Results posted

Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study

A Phase 3 interventional study of Lisdexamfetamine Dimesylate (LDX) in ADHD, sponsored by Shire. Completed at 45 sites in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-14.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
269
Allocation
Not applicable
Ages
13 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.

Enrollment
11th of 51
269 · median 48
Started
2008
with 8 others
Phase 3
15 of 51
none open now
Registered
15th of 51
by date
Lead sponsor
18 of 51
Shire

Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 11th largest by enrollment, is one of 9 that started in 2008, is one of 15 in phase 3, and was the 15th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lisdexamfetamine

lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 13 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the long-term safety of LDX administered as a daily morning dose (30, 50, and 70 mg/day) in the treatment of adolescents (13-17 years of age inclusive at the time of consent).

Read the detailed description

Not Required

03

Conditions studied

04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is a male or female aged 13-17 years inclusive at the time of consent of the antecedent study (SPD489-305).
  2. Subject satisfied all entry criteria for the antecedent study (SPD489-305), and completed a minimum of 3 weeks of double-blind treatment and reached Visit 3 of the antecedent study (SPD489-305), without experiencing any adverse events (AEs) that would preclude exposure to LDX.

Exclusion criteria

Exclusion

  1. Subject was terminated from SPD489-305 for non-compliance and/or experienced a serious adverse event (SAE) or AE resulting in termination from the antecedent study (SPD489-305).
  2. Subject has a current, controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as any severe comorbid Axis II disorder or severe Axis I disorder (such as Post Traumatic Stress Disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder) or other symptomatic manifestations, such as agitated states, marked anxiety, or tension that, in the opinion of the examining clinician, will contraindicate treatment with LDX or confound efficacy or safety assessments. Comorbid psychiatric diagnoses will be established at the Screening Visit (Visit -1) of the antecedent study (SPD489-305) with the Screening interview of the Kiddie-SADS-Present and Lifetime - Diagnostic Interview (K-SADS-PL) and additional modules if warranted by the results of the initial interview. Participation in behavioral therapy, provided the subject was receiving the therapy for at least 1 month at the time of the Baseline Visit (Visit 0) of the antecedent study (SPD489-305).
  3. Subject has a conduct disorder. Oppositional Defiant Disorder is not exclusionary.
  4. Subject is currently considered a suicide risk, has previously made a suicide attempt or has a prior history of, or is currently demonstrating suicidal ideation.
  5. Subject is underweight based on Center for Disease Control and Prevention (BMI)-for-age gender specific charts at the Enrollment Visit (Visit 1) of this study. Underweight is defined as a BMI \< 5th percentile.
  6. Subject has a concurrent chronic or acute illness or unstable medical condition that could confound the results of safety assessments, increase risk to the subject or lead to difficulty complying with the protocol.
  7. Subject has a history of seizures (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder.
  8. Subject has a known history symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug.
  9. Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
  10. Subject has any , based on the Principal Investigator's judgment, at Visit 4/ET of the antecedent study (SPD489-305).
  11. Subject is taking any medication that is excluded.
  12. Subject has a documented allergy, or intolerance to amphetamine.
  13. Subject has a recent history (within the past 6 months) of suspected substance abuse or dependence disorder (excluding nicotine) in accordance with criteria.
  14. Subject has glaucoma.
  15. Subject is taking other medications that have central nervous system (CNS) effects or affect performance, such as sedating antihistamines and decongestant sympathomimetics, or are monoamine oxidase inhibitors. Stable use of bronchodilator inhalers is not exclusionary.
  16. Subject is female and is pregnant or lactating.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
269 participants (actual)

Study arms

  • Experimental
    LDX

    Lisdexamfetamine Dimesylate (LDX)

    Drug: Lisdexamfetamine Dimesylate (LDX)

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline (From the Antecedent Study, SPD489-305) in the Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at up to 52 Weeks

    The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.

    Time frame: Baseline and up to 52 weeks

Secondary outcomes

  1. Percent of Participants With Improvement in Clinical Global Impression-Improvement (CGI-I)

    Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

    Time frame: up to 52 weeks

  2. Change From Baseline (From the Antecedent Study, SPD489-305) in the Youth Quality of Life Instrument-Research Version (YQOL-R) Total Score at up to 52 Weeks

    The Youth Quality of Life-research version (YQOL-R) is a validated 56-item generic instrument for comparing quality of life of adolescents across condition groups that scores each question on a scale from 0 (never) to 4 (very often). The YQOL scores are transformed to a 0-100 scale for easy interpretability. Higher scores indicate better quality of life.

    Time frame: Baseline and Up to 52 weeks

07

Results

Posted Mar 28, 2011

Participant flow

Subjects had to have satisfied all entry criteria for the antecedent study (SPD489-305, NCT00735371) and completed a minimum of 3 weeks of double-blind treatment and reached Visit 3 of the antecedent study (SPD489-305), without experiencing any clinically significant adverse events that would preclude exposure to LDX.

Participant flow — Overall Study
MilestoneLisdexamfetamine Dimesylate (LDX)
Started269
Completed156
Not completed113
Withdrew: Adverse event18
Withdrew: Withdrawal by subject31
Withdrew: Non-compliance16
Withdrew: Lost to follow-up25
Withdrew: Lack of efficacy5
Withdrew: Subject moved7
Withdrew: Pregnancy3
Withdrew: Prohibited medication1
Withdrew: Out of town1
Withdrew: Misuse and compliance of study drug1
Withdrew: Subject sent to boarding school1
Withdrew: Met an exclusion criteria1
Withdrew: Positive drug screen2
Withdrew: Sponsor requested withdrawal1

Outcome measures

PrimaryChange From Baseline (From the Antecedent Study, SPD489-305) in the Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at up to 52 Weeks

The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.

Time frame:
Baseline and up to 52 weeks
Reported as:
Mean · Units on a scale
Change From Baseline (From the Antecedent Study, SPD489-305) in the Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at up to 52 Weeks
Units on a scaleLisdexamfetamine Dimesylate (LDX)
Change From Baseline (From the Antecedent Study, SPD489-305) in the Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at up to 52 Weeks-26.2 ± 9.75
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX) · t-test, 2 sided · p = <0.001t-test of LDX at baseline and 52 weeks
SecondaryPercent of Participants With Improvement in Clinical Global Impression-Improvement (CGI-I)

Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

Time frame:
up to 52 weeks
Reported as:
Number · Percent of participants
Percent of Participants With Improvement in Clinical Global Impression-Improvement (CGI-I)
Percent of participantsLisdexamfetamine Dimesylate (LDX)
Percent of Participants With Improvement in Clinical Global Impression-Improvement (CGI-I)87.2
SecondaryChange From Baseline (From the Antecedent Study, SPD489-305) in the Youth Quality of Life Instrument-Research Version (YQOL-R) Total Score at up to 52 Weeks

The Youth Quality of Life-research version (YQOL-R) is a validated 56-item generic instrument for comparing quality of life of adolescents across condition groups that scores each question on a scale from 0 (never) to 4 (very often). The YQOL scores are transformed to a 0-100 scale for easy interpretability. Higher scores indicate better quality of life.

Time frame:
Baseline and Up to 52 weeks
Reported as:
Mean · Units on a scale
Change From Baseline (From the Antecedent Study, SPD489-305) in the Youth Quality of Life Instrument-Research Version (YQOL-R) Total Score at up to 52 Weeks
Units on a scaleLisdexamfetamine Dimesylate (LDX)
Change From Baseline (From the Antecedent Study, SPD489-305) in the Youth Quality of Life Instrument-Research Version (YQOL-R) Total Score at up to 52 Weeks3.9 ± 9.73
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX) · t-test, 2 sided · p = <0.001t-test of LDX at baseline and 52 weeks

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lisdexamfetamine Dimesylate (LDX)—10/265 (3.8%)230/265 (86.8%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventLisdexamfetamine Dimesylate (LDX)
SyncopeNervous system disorders3/265
AggressionPsychiatric disorders2/265
HydroceleCongenital, familial and genetic disorders1/265
PneumoniaInfections and infestations1/265
Joint SprainInjury, poisoning and procedural complications1/265
Pelvic FractureInjury, poisoning and procedural complications1/265
Traumatic Liver InjuryInjury, poisoning and procedural complications1/265
Wrist FractureInjury, poisoning and procedural complications1/265
Syncope VasovagalNervous system disorders1/265
Ectopic PregnancyPregnancy, puerperium and perinatal conditions1/265
Most frequent other events
Most frequent other events
EventLisdexamfetamine Dimesylate (LDX)
Upper Respiratory Tract InfectionInfections and infestations58/265
Decreased AppetiteMetabolism and nutrition disorders56/265
HeadacheNervous system disorders55/265
Weight DecreasedInvestigations43/265
IrritabilityGeneral disorders33/265
InsomniaPsychiatric disorders32/265
NasopharyngitisInfections and infestations19/265
InfluenzaInfections and infestations18/265
Dry MouthGastrointestinal disorders14/265
DizzinessNervous system disorders14/265

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lisdexamfetamine Dimesylate (LDX)
Mean14.5 ± 1.30
Age, Customized
Age, Customized(Participants)Lisdexamfetamine Dimesylate (LDX)
13 to 14 years144
15 to 17 years121
Sex: Female, Male
Sex: Female, Male(Participants)Lisdexamfetamine Dimesylate (LDX)
Female78
Male187
Region of Enrollment
Region of Enrollment(Participants)Lisdexamfetamine Dimesylate (LDX)
United States265
08

Study locations

45 sites
  • Clinical Study Centers, LLC
    Little Rock, Arkansas 72205, United States
  • Valley Clinical Research, Inc.
    El Centro, California 92243, United States
  • Penninsula Research Associates, Inc.
    Rolling Hills Estates, California 90274, United States
  • Psychiatric Centers at San Diego (PCSD-Feighner Research Institute)
    San Diego, California 92108, United States
  • Elite Clinical Trials, Inc.
    Wildomar, California 92595, United States
  • Florida Clinical Research Center, LLC
    Bradenton, Florida 34208, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • Amedica Research Institute, Inc.
    Hialeah, Florida 33013, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32216, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32806, United States
  • Miami Research Associates
    South Miami, Florida 33143, United States
  • Janus Center for Psychiatric Research
    West Palm Beach, Florida 33407, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • Northwest Behavioral Research Center
    Marietta, Georgia 30060, United States
  • Capstone Clinical Research
    Libertyville, Illinois 60048, United States
  • Clinco Inc.
    Terre Haute, Indiana 47802, United States
  • CIENTIFICA, Inc. at Prairie View
    Newton, Kansas 67114, United States
  • Psychiatric Associates
    Overland Park, Kansas 66211, United States
  • Vince and Associates Clinical Research, Inc.
    Overland Park, Kansas 66212, United States
  • Pedia Research LLC.
    Owensboro, Kentucky 42301, United States
  • Four Rivers Clinical Research, Inc.
    Paducah, Kentucky 42003, United States
  • Louisiana Research Associates, Inc.
    New Orleans, Louisiana 70114, United States
  • Bart Sangal
    Troy, Michigan 48085, United States
  • Center for Psychiatry and Behavioral Medicine, Inc.
    Las Vegas, Nevada 89128, United States
  • Children's Specialized Hospital
    Toms River, New Jersey 08755, United States
  • Bioscience Research, LLC
    Mount Kisco, New York 10549, United States
  • Triangle Neuropsychiatry, PLLC
    Durham, North Carolina 27707, United States
  • Innovis Health/Odyssey Research
    Fargo, North Dakota 58104, United States
  • University Hospitals of Cleveland Division of Child & Adolescent Psychiatry
    Cleveland, Ohio 44106, United States
  • IPS Research Company
    Oklahoma City, Oklahoma 73103, United States
  • OCCI
    Eugene, Oregon 97401, United States
  • Summit Research Network
    Portland, Oregon 97210, United States
  • OCCI, INC (Oregon Center for Clinical Investigations, Inc.)
    Salem, Oregon 97301, United States
  • CRI Worldwide
    Philadelphia, Pennsylvania 19139, United States
  • Youth and Family Research Program/WPIC ADHD Research Program
    Pittsburgh, Pennsylvania 15213, United States
  • CNS Healthcare
    Memphis, Tennessee 38119, United States
  • Future Search Trials
    Austin, Texas 78756, United States
  • Bayou City Research, Ltd.
    Houston, Texas 77007, United States
  • Red Oak Psychiatry Associates P.A.
    Houston, Texas 77090, United States
  • ADHD Clinic of San Antonio
    San Antonio, Texas 78247, United States
  • Vermont Clinical Study Center
    Burlington, Vermont 05401, United States
  • Neuropsychiatric Associates
    Woodstock, Vermont 05091, United States
  • Neuroscience, Inc.
    Herndon, Virginia 20170, United States
  • Dominion Clinical Research
    Midlothian, Virginia 23112, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98004, United States
09

References and documents

Publications

  • Findling RL, Cutler AJ, Saylor K, Gasior M, Hamdani M, Ferreira-Cornwell MC, Childress AC. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2013 Feb;23(1):11-21. doi: 10.1089/cap.2011.0088. PubMed 23410138 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2008 to primary completion in Apr 2010, 17 months.

Results were first posted in Mar 2011, 11 months after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 17 months is above that.

Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2008
First posted
Oct 2, 2008
StartActual
Nov 13, 2008
Primary completionActual
Apr 22, 2010
CompletionActual
Apr 22, 2010
Results first posted
Mar 28, 2011
Last update
Jun 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00764868
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Oct 2, 2008
Start date
Nov 13, 2008
Primary completion
Apr 22, 2010
Completion
Apr 22, 2010
Results posted
Mar 28, 2011
Last update
Jun 14, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion